Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Good results seen with laparoscopic partial nephrectomy following selective embolization of tumor

Benoit M et al. Clinical Genitourinary Cancer: Published online 12 July 2018 https://doi.org/10.1016/j.clgc.2018.07.005.

Key clinical point: The short-term oncological and functional outcomes for partial nephrectomy are comparable for laparoscopic partial nephrectomy following selective embolization of tumor (LPNE) in a hybrid operating room and robot-assisted partial nephrectomy (RAPN). A longer follow-up and a larger cohort of patients would be necessary to verify the benefits of LPNE, which appears to be a very interesting alternative to RAPN.

Major finding: There was no difference between oncological and functional outcomes, with a positive surgical margins (PSM) rate of 4.4% for the 57 patients who had LPNE and of 10.3% for the 48 patients who had RAPN (p=0.32). Further, the mean change in estimated glomerular filtration rate (eGFR) at 1 month was -5.5% for LPNE and -8.3% for RAPN (p=0.17). The mean operative time was shorter in the LPNE group (150 vs 195 min, p less than 0.001), and mean estimated blood loss was less in the LPNE group (185 vs 345 mL, p=0.04).

Study details: All patients who underwent a LPNE at Angers (France) University Hospital between May 2015 and April 2017, and a RAPN at Diaconesses Croix Saint Simon, Paris, between October 2014 and April 2017, were prospectively included. The functional outcomes were evaluated using the change of estimated glomerular filtration rate (eGFR) at 1 month, and the oncological outcomes were evaluated using the positive surgical margins (PSM) rate.

Disclosures: The authors had no relevant financial disclosures.

Source: Benoit M et al. Clinical Genitourinary Cancer: Published online 12 July 2018 https://doi.org/10.1016/j.clgc.2018.07.005

Citation:

Benoit M et al. Clinical Genitourinary Cancer: Published online 12 July 2018 https://doi.org/10.1016/j.clgc.2018.07.005

This Week's Must Reads

Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Must Reads in Renal Cell Carcinoma

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001